Please login to the form below

Not currently logged in
Email:
Password:

Adocia names senior members of new US subsidiary

Simon Bruce and Stephen Daly join from Halozyme

edit-Adocia-Simon-BruceBiotech Adocia has named two senior members of its team that will be based at its new subsidiary in the US.

Simon Bruce (top pictured) has been named as chief medical officer, while Stephen Daly has been appointed as US commercial lead and will be in charge of the business development in the US in addition to US investor relations.

Bruce has over 15 years of experience in drug development and registrational drug trials. He joins from Halozyme Pharmaceuticals, where he held the position of executive medical director and worked on the ultra-rapid insulin programme.

Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon's phase III studies and safety analysis, a once weekly GLP-1 injectable formulation.

Daly has 24 years of experience in commercialisation and business development for pharma and biotech products across multiple therapeutic categories. He most recently served as VP of commercial at Halozyme, also on the ultra-rapid insulin programme.

Daly's experience in the diabetes field also includes several years at Amylin, where he worked on the marketing and brand leadership for Byetta and Symlin.

edit-Adocia-Stephen-Daly

Olivier Soula, R&D director and deputy general manager at Adocia, commented: “Their knowledge and experience in drug development, especially in the diabetes field, are unique from both medical and commercial perspective.

“They are indisputable assets to accelerate the development and commercialisation of our projects and to optimise our collaborative research in partnerships."

9th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics